Literature DB >> 12210449

Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results.

Dawn Elizabeth McNeil1, Timothy R Coté, Limin Clegg, Lucy Balian Rorke.   

Abstract

BACKGROUND: It has been suggested that cerebellar medulloblastoma (M) and primitive neuroectodermal tumors (PNET) arising elsewhere in the nervous system, represent a single entity (M/PNET), although this concept is controversial. Cancer registries permit population-based description of cases reported as medulloblastoma, those reported as PNET and description of the aggregate, M/PNET. PROCEDURE: We reviewed the 768 cases of M/PNET (633 diagnosed medulloblastoma and 135 diagnosed PNET) among persons under 20 years of age in the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) database.
RESULTS: The incidence of M/PNET rose 23%, from 4 per 10(6) person-years in 1973-77 to 4.9 per 10(6) person-years in 1993-98. Cases reported as PNET were more likely than those reported as medulloblastoma to be supratentorial (30.4% vs. 1.9%, P < 0.001) and to be female (42.2% vs. 35.4%, P = 0.13). The difference in 5-year survival between the 600 children with infratentorial medulloblastoma vs. the 49 children with infratentorial PNET was not statistically significant (55% vs. 43%). Regardless of reporting diagnosis, survival was poorer among children age 0-3 years and those with supratentorial tumors. Children diagnosed in the more recent period from 1985-1998 had a longer median survival than children diagnosed in 1973-84 (4.9 years vs. 10 years, P < 0.05). Rates were 42% higher among Whites compared to Blacks (4.5/10(6) person-years vs. 3.1/10(6) person-years, P < 0.01).
CONCLUSIONS: We found M/PNET is increasing in incidence and more frequent among Whites. Given that medulloblastoma and PNET are histologically identical and have similar epidemiologic profiles, future studies should provide analyses that combine these entities. Published 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12210449     DOI: 10.1002/mpo.10121

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  53 in total

1.  Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.

Authors:  Annette Künkele; Katleen De Preter; Lukas Heukamp; Theresa Thor; Kristian W Pajtler; Wolfgang Hartmann; Michel Mittelbronn; Michael A Grotzer; Hedwig E Deubzer; Frank Speleman; Alexander Schramm; Angelika Eggert; Johannes H Schulte
Journal:  Neuro Oncol       Date:  2012-05-16       Impact factor: 12.300

2.  A paediatric supratentorial primitive neuroectodermal tumour associated with malignant astrocytic transformation and a clonal origin of both components.

Authors:  Susanne A Kuhn; Uwe-Karsten Hanisch; Kristian Ebmeier; Christian Beetz; Michael Brodhun; Rupert Reichart; Christian Ewald; Thomas Deufel; Rolf Kalff
Journal:  Neurosurg Rev       Date:  2007-02-27       Impact factor: 3.042

3.  Long-term relapse-free survival with supratentorial primitive neuroectodermal tumor in an adult: a case report.

Authors:  Thomas Krampulz; Volkmar H Hans; Falk Oppel; Uwe Dietrich; Maximilian J A Puchner
Journal:  J Neurooncol       Date:  2006-03-10       Impact factor: 4.130

Review 4.  Unraveling the therapeutic potential of the Hedgehog pathway in cancer.

Authors:  Dereck Amakye; Zainab Jagani; Marion Dorsch
Journal:  Nat Med       Date:  2013-11-07       Impact factor: 53.440

Review 5.  Primitive neuroectodermal tumours (PNETs) located in the spinal canal; the relevance of classification as central or peripheral PNET : case report of a primary spinal PNET occurrence with a critical literature review.

Authors:  W A Kampman; J M Kros; T H R De Jong; M H Lequin
Journal:  J Neurooncol       Date:  2005-11-15       Impact factor: 4.130

6.  Incidence of medulloblastoma in Canadian children.

Authors:  Donna L Johnston; Daniel Keene; Maria Kostova; Douglas Strother; Lucie Lafay-Cousin; Chris Fryer; Katrin Scheinemann; Anne-Sophie Carret; Adam Fleming; Vanessa Percy; Samina Afzal; Beverly Wilson; Lynette Bowes; Shayna Zelcer; Chris Mpofu; Mariana Silva; Valerie Larouche; Josee Brossard; Eric Bouffet
Journal:  J Neurooncol       Date:  2014-08-17       Impact factor: 4.130

Review 7.  The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis.

Authors:  Paula de Robles; Kirsten M Fiest; Alexandra D Frolkis; Tamara Pringsheim; Callie Atta; Christine St Germaine-Smith; Lundy Day; Darren Lam; Nathalie Jette
Journal:  Neuro Oncol       Date:  2014-10-13       Impact factor: 12.300

8.  Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.

Authors:  Nadia Barahmani; Sarah Carpentieri; Xio-Nan Li; Tao Wang; Yumei Cao; Laura Howe; Lindsay Kilburn; Murali Chintagumpala; Ching Lau; M Fatih Okcu
Journal:  Neuro Oncol       Date:  2008-10-24       Impact factor: 12.300

9.  Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways.

Authors:  Fan Yang; Veronica Jove; Hong Xin; Michael Hedvat; Timothy E Van Meter; Hua Yu
Journal:  Mol Cancer Res       Date:  2010-01-06       Impact factor: 5.852

10.  Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma.

Authors:  Surya Rednam; Michael E Scheurer; Adekunle Adesina; Ching C Lau; Mehmet Fatih Okcu
Journal:  Pediatr Blood Cancer       Date:  2012-10-12       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.